New headquarter in Krakow

Selvita, one of the largest preclinical CROs in Europe, continued its growth strategy with the completion of its new headquarters in Krakow, Poland. The 4,000 m2 Selvita Research Center is part of the CRO’s strategy to bolster organic growth. The move will allow the company to expand operations in drug development and analytical testing at its current facilities nearby. The new location will also offer a range of drug discovery labs including medicinal chemistry, biochemistry, in vitro biology, ADME/DMPK and in vivo pharmacology. “At Selvita, we understand that access to state-of-the-art infrastructure and scientific technology platforms is crucial for the continued organic growth of a research organisation aiming at scientific excellence,” Miroslawa Zydron, Selvita’s Chief Operating Officer, said. “We invested in construction of our own facility, ensuring that the labs we move into will be fully adapted to our needs and will contribute to the success of our partners’ projects.”